Unauthorized Use of Content on this Site: The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB)—including, but not limited to, those available through the PAAB Forum, the PAAB website, and any PAAB correspondence—are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content, or using it for model training or any related purposes, is strictly prohibited without the express prior written consent of PAAB. This includes, but is not limited to, the use of such materials in automated systems, machine learning models, or artificial intelligence applications.
Mention of positive LOI with pCPA
-
Is it permissible to include a callout in a branded APS that simply mentions a positive LOI with pCPA for a particular indication, once that agreement has been publicized? Appropriate balance information would be included.
-
Hello @karen-taylor
Please see the response to Q&A Email update on CADTH recommendations. The letter of intent (LOI) is viewed similarly to the CADTH recommendation. It is not acceptable to position the pan-Canadian Pharmaceutical Alliance (pCPA) coverage negotiations as a positive feature of the product or suggest endorsement. Formulary messages should be restricted to clear, complete coverage criteria and not suggest the endorsement of a product.
